title: Targeted delivery of VEGF to treat myocardial infarction.
abstract: Noninvasive injection of pro-angiogenic compounds such as vascular endothelial growth factor (VEGF) has shown promising results in regenerating cardiac microvasculature. However, these results have failed to translate into successful clinical trials in part due to the short half-life of VEGF in circulation. Increasing the dose of VEGF may increase its availability to the target tissue, but harmful side-effects remain a concern. Encapsulating and selectively targeting VEGF to the MI border zone may circumvent these problems. Anti-P-selectin conjugated immunoliposomes containing VEGF were developed to target the infarct border zone in a rat MI model. Targeted VEGF therapy significantly improves vascularization and cardiac function after an infarction.
authors.affiliation: Temple University, 1947 North 12th Street, Philadelphia, PA, 19140, USA.|Widener University, Chester, PA, USA.
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.affiliation: Temple University, 1947 North 12th Street, Philadelphia, PA, 19140, USA.
authors.forename: Rabe'e
authors.initials: R
authors.lastname: Cheheltani
authors.affiliation: Temple University, 1947 North 12th Street, Philadelphia, PA, 19140, USA.
authors.forename: Jenna
authors.initials: J
authors.lastname: Rosano
authors.affiliation: Temple University, 1947 North 12th Street, Philadelphia, PA, 19140, USA.
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Crabbe
authors.affiliation: Temple University, 1947 North 12th Street, Philadelphia, PA, 19140, USA. mkiani@temple.edu.
authors.forename: Mohammad F
authors.initials: MF
authors.lastname: Kiani
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems; D006207:Half-Life; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008081:Liposomes; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D019007:P-Selectin / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D008081:Liposomes; D019007:P-Selectin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A